Back to top
more

Centene (CNC)

(Delayed Data from NYSE)

$70.84 USD

70.84
5,387,498

+0.01 (0.01%)

Updated Sep 9, 2024 04:00 PM ET

After-Market: $70.82 -0.02 (-0.03%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (212 out of 249)

Industry: Medical - HMOs

Better trading starts here.

Zacks News

Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.

Varian (VAR) Rides on Diverse Product Line, Competition Rife

Varian Medical (VAR) has a strong international presence and growing proton therapy market. However, intense competition adds to woes.

    Stryker Closes Entellus Buyout, Bolsters Neurotechnology Line

    Stryker (SYK) maintains its acquisition-driven strategy to provide superior and more economic patient experiences.

      Cardiovascular Systems Gains From 510K for OrbusNeich Device

      Cardiovascular Systems (CSII) to distribute limited editions of both 1.0-4.0mm Sapphire II PRO and 2.0-4.0mm Sapphire NC Plus non-compliant coronary balloons post the product launches in the market.

        Universal Health (UHS) Q4 Earnings, Revenues Beat Estimates

        Solid segmental performance drives Universal Health's (UHS) fourth-quarter results.

          Community Health's (CYH) Q4 Loss Narrower Than Expected

          Lower admission hurts Community Health's (CYH) fourth-quarter results.

            Veeva Systems (VEEV) Q4 Earnings Top, FY19 View Promising

            Veeva Systems (VEEV) continues to witness year-over-year growth on earnings and revenues backed by the company's consistent efforts in product innovation and launches via R&D.

              Zacks.com highlights: Centene, Andersons, Builders FirstSource, United Continental Holdings and Dillard's

              Zacks.com highlights: Centene, Andersons, Builders FirstSource, United Continental Holdings and Dillard's

                Envision Healthcare (EVHC) Q4 Earnings Beat, Revenues Rise

                Envision Healthcare (EVHC) earnings benefited from higher revenues partly offset by an increase in expenses.

                  Allscripts' (MDRX) Fundamentals Strong Amid Stiff Competition

                  Allscripts' (MDRX) promising fourth-quarter results and international hold are encouraging. Integration risks and cutthroat competition are likely to mar prospects.

                    Masimo Products to Boost India-Based NU Hospitals' Systems

                    Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.

                      Tenet Healthcare (THC) Q4 Earnings & Revenues Top Estimates

                      Strong segmental performances along with solid expense management aid Tenet Healthcare's (THC) Q4.

                        5 Stocks to Bet on Following Recent Broker Rating Upgrades

                        With multiple earnings reports flooding the market, determining the outperformers is by no means an easy task for individual investors.

                          LifePoint Health (LPNT) Q4 Earnings Miss on Lower Revenues

                          LifePoint Health (LPNT) fails to beat the earnings and revenue estimates in the fourth quarter. Equivalent admissions decline 3% year over year.

                            Here's Why You Must Add Haemonetics (HAE) to Your Portfolio

                            Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.

                              Varian (VAR) Acquires Evinance to Boost Oncology Segment

                              Varian Medical Systems (VAR) acquires Evinance to improve cancer care through CDS software. The company also expects to gain from flagship ARIA's recent certification.

                                Express Scripts, Walgreens Tie Up to Cut Specialty Drug Price

                                Express Scripts (ESRX) expands group purchasing effort with Walgreens Boots Alliance to simplify supply chains and make specialty drugs affordable.

                                  International Business Aids NuVasive, Pricing Woe Remains

                                  NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.

                                    Cerner Partnering With Surescripts to Revamp EHR Platform

                                    Cerner (CERN) will introduce Surescripts' Real-Time Prescription Benefit functionality into "Cerner Millennium's" EHR platform to help clients curtail escalating healthcare costs.

                                      BD (BDX) Launches PAXgene in Europe for Advanced DNA Testing

                                      Becton, Dickinson and Company's (BDX) PAXgene ccfDNA gets a commercial launch in Europe and enables improved DNA testing in comparison to standard EDTA tubes.

                                        NuVasive's SpineTRACK Registry Gains New CMS Designation

                                        NuVasive's (NUVA) receipt of the QCDR designation for its SpineTRACK buoys optimism for the stock. This achievement might add value to cushion its efforts to provide systems-based spine solutions.

                                          Luminex (LMNX) Banks on Solid Product Line, Competition Rife

                                          Luminex's (LMNX) extensive product line and rising revenues raise optimism. However, a challenging reimbursement scenario is likely to mar prospects.

                                            Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis

                                            Abiomed (ABMD) gets second FDA PMA for its flagship Impella in a row, with a view to treating patients with High Risk PCI.

                                              Hologic Banks on Diagnostics, GYN Surgical Prospects Bright

                                              Hologic (HOLX) stays upbeat about GYN Surgical on the recent commercial launch of MyoSure MANUAL device in the United States.

                                                Pharmacy Services Aid CVS Health, Aetna Deal an Upside Too

                                                CVS Health (CVS) is likely to earn $750 million from near-term synergies after the completion of Aetna acquisition deal.

                                                  Inogen (INGN) Gains on Diverse Product Line, Competition Rife

                                                  Inogen (INGN) rides on POC growth. Existing market challenges likely to mar prospects.